Content
Search
Navigation
Sitemap
About us
View this section
View this section
Who we are
Our model
Our investment process
Our purpose, culture and values
Our history
Overview
test standard content page
A second standard page
Our people
View this section
View this section
Board of Directors
Portfolio
View this section
View this section
Portfolio data
Cell therapy
Overview
Autolus Therapeutics
Achilles Therapeutics
Quell Therapeutics
Resolution Therapeutics
Clade Therapeutics
Gene Therapy
Overview
Beacon Therapeutics
Freeline Therapeutics
SwanBio Therapeutics
Purespring Therapeutics
Biologics
Overview
Anaveon
Small molecule
Overview
OMass Therapeutics
Mosaic Therapeutics
Kesmalea Therapeutics
Previous investments
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
Neogene Therapeutics
14MG
Azeria Therapeutics
Sustainability
View this section
View this section
Message from CEO, SIML
Our approach to sustainability reporting
Our social impact
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Inspiring and empowering our people
Responsible and ethical business
Overview
Environment
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and insights
View this section
View this section
News
Insights & articles
Publications & presentations
Investors
View this section
View this section
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
Our Committees
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Portfolio data
Browse all portfolio data news
Search
Latest portfolio data news
Show news from
all companies
all companies
all Cell therapy companies
Autolus Therapeutics
Achilles Therapeutics
all Gene Therapy companies
Freeline Therapeutics
all Biologics companies
Anaveon
all Small molecule companies
Clear filters
06.07.23
Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia
Cell therapy
Autolus Therapeutics
27.06.23
Autolus Therapeutics announces publication in Cancer Immunology Research
Cell therapy
Autolus Therapeutics
16.06.23
Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
Cell therapy
Autolus Therapeutics
02.06.23
Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO
Cell therapy
Autolus Therapeutics
26.04.23
Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting
Operating News
Cell therapy
Autolus Therapeutics
06.12.22
Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022
Operating News
Cell therapy
Achilles Therapeutics
Load more
Close menu
About us
View this section
View this section
Who we are
Our model
Our investment process
Our purpose, culture and values
Our history
Overview
test standard content page
A second standard page
Our people
View this section
View this section
Board of Directors
Portfolio
View this section
View this section
Portfolio data
Cell therapy
Overview
Autolus Therapeutics
Achilles Therapeutics
Quell Therapeutics
Resolution Therapeutics
Clade Therapeutics
Gene Therapy
Overview
Beacon Therapeutics
Freeline Therapeutics
SwanBio Therapeutics
Purespring Therapeutics
Biologics
Overview
Anaveon
Small molecule
Overview
OMass Therapeutics
Mosaic Therapeutics
Kesmalea Therapeutics
Previous investments
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
Neogene Therapeutics
14MG
Azeria Therapeutics
Sustainability
View this section
View this section
Message from CEO, SIML
Our approach to sustainability reporting
Our social impact
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Inspiring and empowering our people
Responsible and ethical business
Overview
Environment
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and insights
View this section
View this section
News
Insights & articles
Publications & presentations
Investors
View this section
View this section
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
Our Committees
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Search
Search